Achillion Pharmaceuticals, Inc. (ACHN) Tops Q3 EPS by 1c, Sales Miss Expectations

November 8, 2011 7:12 AM EST
Achillion Pharmaceuticals, Inc. (NASDAQ: ACHN) reported Q3 EPS of ($0.15), $0.01 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $64 thousand versus the consensus estimate of $130 thousand.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Earnings